Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527681 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
A Phase 1 study, sponsored by Basilea Pharmaceutica.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02527681 is a Phase 1 study that was terminated before completion, run by Basilea Pharmaceutica. The registered enrollment target is 15 participants.
The verdict
NCT02527681, a Phase 1 study, was terminated before completion, sponsored by Basilea Pharmaceutica.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
Interventions
- DRUG Ceftobiprole medocaril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-11-22 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02527681
The ClinicalTrials.gov registry entry for NCT02527681 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceftobiprole medocaril is the first listed.
NCT02527681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02527681 about?
NCT02527681 is a clinical study titled "Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics". This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
What is the current status of trial NCT02527681?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-11-22. Estimated completion is 2020-02-25.
What interventions are being tested in trial NCT02527681?
The interventions under investigation include: Ceftobiprole medocaril (DRUG).
Who is sponsoring clinical trial NCT02527681?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.